Celebration Thread! Biogen is going to the FDA with Aducan.

Alzheimer's, cardiovascular, and other chronic diseases; biomarkers, lifestyle, supplements, drugs, and health care.
J11
Contributor
Contributor
Posts: 3351
Joined: Sat May 17, 2014 4:04 pm

Re: Celebration Thread! Biogen is going to the FDA with Aducan.

Post by J11 »

All amyloid ordered intermixed.png
You do not have the required permissions to view the files attached to this post.
J11
Contributor
Contributor
Posts: 3351
Joined: Sat May 17, 2014 4:04 pm

Re: Celebration Thread! Biogen is going to the FDA with Aducan.

Post by J11 »

tau ordered intermix amyloid.png
tau ordered intermix.png
You do not have the required permissions to view the files attached to this post.
J11
Contributor
Contributor
Posts: 3351
Joined: Sat May 17, 2014 4:04 pm

Re: Celebration Thread! Biogen is going to the FDA with Aducan.

Post by J11 »

The two figures above are particularly noteworthy.
For some reason the figures did not align properly on the page.
With these paired figures it is best to have them so that they are align so that it is easy to see
how the patients in the figures correspond to each other.

Notice that in the top figure that until ~225 as marked on the x-axis, there are only a few patients with positive amyloid change. Now look at the corresponding region in the bottom figure. These first ~225 patients all had substantial tau 181 reduction. The correlation approach did not bring this to the forefront, though these figures are able to show this feature of the dataset. given that a patient had substantial tau 181 reduction, then it is almost 100% certain that SUVR amyloid change was negative or very close to being negative.

The reverse, having a sharp tau 181 increase (to the right of the figure) is not as strictly related to amyloid as was true with the tau decrease, though the larger red columns above the line in the top figure tend to be towards the right side.

Notice, however, that the logic does not imply that all those with large amyloid decreases will also have large tau decreases. It is more that almost none with large amyloid increases had large tau decreases.
J11
Contributor
Contributor
Posts: 3351
Joined: Sat May 17, 2014 4:04 pm

Re: Celebration Thread! Biogen is going to the FDA with Aducan.

Post by J11 »

Top tau magnitude.png
Top tau.png
All tau amyloid intermix.png
You do not have the required permissions to view the files attached to this post.
J11
Contributor
Contributor
Posts: 3351
Joined: Sat May 17, 2014 4:04 pm

Re: Celebration Thread! Biogen is going to the FDA with Aducan.

Post by J11 »

All amyloid together.png
All amyloid by dose.png
You do not have the required permissions to view the files attached to this post.
J11
Contributor
Contributor
Posts: 3351
Joined: Sat May 17, 2014 4:04 pm

Re: Celebration Thread! Biogen is going to the FDA with Aducan.

Post by J11 »

amyloid ordered intermix.png
amyloid ordered intermix tau change.png
You do not have the required permissions to view the files attached to this post.
J11
Contributor
Contributor
Posts: 3351
Joined: Sat May 17, 2014 4:04 pm

Re: Celebration Thread! Biogen is going to the FDA with Aducan.

Post by J11 »

Leca Phase 2b 10 p mva tau.png
You do not have the required permissions to view the files attached to this post.
J11
Contributor
Contributor
Posts: 3351
Joined: Sat May 17, 2014 4:04 pm

Re: Celebration Thread! Biogen is going to the FDA with Aducan.

Post by J11 »

This is an especially insightful figure. I had not been aware of these column and line figures before, though they are able to add in another dimension of information and add great value to communicating the meaning of the data.

What we have above is the leca set ranked by amyloid. This information is added to the figure by the secondary y-axis on the right and the shading. To read this information start at a value on the right of say -0.30 ---> follow to the left and then meet up with the shading at around patient 45 on the x-axis. So the 45th patient in the leca trial ordered by amyloid had ~-0.30 amyloid removal.

The left y-axis allow us to see what the tau 181 change was for a moving average of 10 patients. This takes away the data noise that we saw on the other figures. What we see here is a very clear relationship between amyloid removal and tau response. tau is low on the left when there is a great deal of amyloid removal and tau is high on the right when there is minimal amyloid removal. Notably there is a great flat area in the middle where amyloid removal has somewhat more tau effect than might be expected. This relationship is so strong that I will try and redo this to make sure there are no errors. This would be a great figure to repeat for the entire dataset. It is a bit tricky though to make these column and line figures. The trick is to put the data for the line in the column right beside the column dataset.
J11
Contributor
Contributor
Posts: 3351
Joined: Sat May 17, 2014 4:04 pm

Re: Celebration Thread! Biogen is going to the FDA with Aducan.

Post by J11 »

All ordered amyloid tau 10 point mva.PNG
You do not have the required permissions to view the files attached to this post.
J11
Contributor
Contributor
Posts: 3351
Joined: Sat May 17, 2014 4:04 pm

Re: Celebration Thread! Biogen is going to the FDA with Aducan.

Post by J11 »

This replicates the leca result posted above for the entire dataset. As seen as soon as amyloid removal is more than ~0.10 SUVR, then there is a nearly consistently strong tau reduction. This is a fairly impressive result that I will want to double check on again. With this figure one can understand the problem that arose during anti-amyloid therapies.
When anti-amyloids only removed between ~-0.05 and ~-0.15, there would be a great deal of uncertainty about the effect on tau even with largish samples. It was only with mabs that could remove ~0.20 amyloid that consistent reduction in tau and then perhaps cognitive benefit could be expected.
Post Reply